JUJosé Ursic-Bedoya

José Ursic-Bedoya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


José Ursic-Bedoya has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of available scoring systems in liver transplantation for severe acute-on-chronic liver failure (ACLF)

    by Sébastien L’HErmite, Isaure Breteau, Sébastien Halter, Nicolas Jacquinot, Valentin Coirier, José Ursic-Bedoya, Giovanni Perricone, Laure Elkrief, Philippe Ichai, Audrey Coilly, et al.

    The Transplantation for ACLF-3 Model (TAM) and Sundaram ACLF-LT-Mortality score (SALT-M) have been proposed to help select liver transplantation (LT) candidates with acute-on-chronic liver failure (ACLF) to optimize post-LT outcomes. We assessed the performance and clinical utility of these scores and their components on a large retrospective international multicenter study. All patients transplanted in the context of ACLF grade 3 (n=336) from 9 international cohorts (2008–2024) were included in the study. The primary endpoint was 1-year post-LT survival. Score discrimination, calibration, and clinical utility using decision-curve (net benefit) analysis were assessed. The 1-year post-LT survival rate was 75.3%. Both TAM (OR 1.91, p =0.0001) and SALT-M (OR 1.09, p 25 (46.9% vs. 78.7%). Respiratory failure (PaO 2 /FiO 2 ≤200) was associated with 1-year post-LT mortality, whereas other variables included in the original scores, diabetes, BMI, and leukocyte count, did not demonstrate significant prognostic value in this cohort. In this large multicenter study, TAM and SALT-M were associated with post-LT mortality but demonstrated limited discriminative accuracy. Candidate high-risk thresholds (TAM ≥3, SALT-M >25) may help identify a small subset of patients with markedly poor post-LT outcomes. However, given their modest performance, these scores should support, not replace, multidisciplinary decision-making, and their applicability should be evaluated in a prospective fashion.

  • Open Access

    Pre‐ TIPS Liver and Spleen Volumetry Are Not Associated With Liver‐Related Outcomes After TIPS Placement for Refractory Ascites

    by José Ursic Bedoya, Mathilde Wagner, Emilie Malézieux, Paul Primard, Hélène Larrue, Sarah Mouri, Charlotte Bouzbib, Marion Soler, Christophe Bureau, Nicolas Molinari, et al.

    Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) improves survival in refractory ascites. A careful patient's selection is mandatory as TIPS can lead to complications. Liver volumetry is predictive of outcomes before hepatic surgery, but data on its role before TIPS placement are scarce. We aimed to evaluate whether liver and spleen volume measurements are associated with prognosis after TIPS placement in patients with ascites. Methods: We analysed data from three French centers, treated with TIPS between 2017 and February 2022. Inclusion criteria encompassed a TIPS placement for refractory or recurrent ascites and availability of cross‐sectional imaging. Exclusion criteria included non‐cirrhotic portal hypertension, other indications for TIPS, hepatocellular carcinoma beyond Milan criteria, and extrahepatic malignancy. Liver and spleen volumes were measured using pre‐TIPS CT or MRI scans. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoints were overt hepatic encephalopathy (HE), recurrence of ascites, acute variceal bleeding, and jaundice. Results: The 160 patients were included (median age 60 years, male gender 83.8%, alcohol‐related cirrhosis 58.8%, with active alcohol consumption in 25.6%, Child‐Pugh B cirrhosis in 81.2%, median MELD score was 12). The 1‐year TFS was 60.1%. Multivariate analysis identified serum creatinine (HR = 1.01 95% CI [1.00–1.01], p = 0.04), total bilirubin (HR = 1.02 95% CI [1.02–1.04], p = 0.004), and portal pressure gradient (HR = 1.09 95% CI [1.01–1.18], p = 0.03) as independent factors associated with TFS. Neither liver‐to‐spleen volume ratios (LSVR) ( p = 0.36) nor liver volume index ( p = 0.92) were significantly associated with death or LT. Overall, 38.1% of patients developed overt HE after TIPS, with lower platelet count (HR = 1.01 95% CI [1.00–1.01], p = 0.04) emerging as an independent predictor. No radiological characteristics were associated with the recurrence of ascites. Conclusions: In this multicenter study, liver and spleen volumes were not associated with transplant‐free survival or liver‐related outcomes in patients undergoing TIPS for ascites. These findings suggest that liver volumetry should not be a determining factor in patient selection for TIPS placement.


  • Coopération oncogénique et effets métaboliques de FGF19 dans le carcinome hépatocellulaire

    by José Ursic Bedoya

    Le carcinome hépatocellulaire (CHC) est la tumeur maligne primitive hépatique la plus fréquente et se situe au 6e et 3ème rang en termes de fréquence et de mortalité liées au cancer, respectivement. La surexpression de FGF19 est un évènement fréquent dans les CHC humains et des molécules ciblant FGF19 ou son récepteur tyrosine kinase dans le foie (Fibroblast Growth Factor Receptor 4 FGFR4) sont en cours d’étude. Chez la souris l’exposition à des concentrations élevées de FGF19 au long cours provoque une tumorigénèse hépatique. Par ailleurs, FGF19 exerce de nombreux effets métaboliques ayant pour conséquence une protection contre l’insulinorésistance. Ainsi, des molécules analogues à FGF19 sont également en cours d’étude pour traitement de maladies métaboliques, comme la stéatohépatite non alcoolique (ou NASH pour Non alcoholic steatohepatitis). Dans ce contexte, notre projet avait pour but de mieux caractériser les effets oncogéniques et métaboliques de FGF19 dans un modèle de souris immunocompétentes.En utilisant la technique de transfection hydrodynamique des hépatocytes, nous avons obtenu des souris C57Bl6/J ayant une expression de FGF19 persistante, avec des concentrations circulantes supra-physiologiques, associée à l’inhibition de la voie de synthèse des acides biliaires. Nous avons découvert chez ces souris un phénotype de diabète insipide, caractérisé par une polydipsie et une dilution des urines persistant dans le temps. Cet effet est similaire à celui qui a déjà été décrit pour FGF21, une molécule appartenant à la même famille que FGF19. Cependant, l’effet de FGF19 est indépendant de FGF21 et est retrouvé également lorsqu’une tumeur surexprimant FGF19 est injectée par voie orthotopique.Par ailleurs, l’expression de FGF19, seule ou avec l’invalidation simultanée de p53 par la technique de CRISPR-Cas9, donne des CHC bien différenciés après 9-12 mois. La combinaison FGF19 avec une surexpression de C-Myc, avec ou sans l’invalidation de p53, induit le développement de volumineuses tumeurs moyennement différenciées apparaissant après 2-3 semaines seulement. La comparaison avec la tumorigenèse déclenchée par C-Myc seul ou par C-Myc/ CRISPR-p53, fait apparaître une coopération entre Myc et FGF19 donnant lieu à l’accélération très significative de l’oncogenèse par FGF19. L’analyse transcriptomique et histologique de ces tumeurs met en évidence une stimulation de la néoangiogénèse par FGF19. Enfin, dans un modèle de régime pourvoyeur de NASH, l’expression tumorale de FGF19 exerce un effet paradoxal : tout en accélérant la croissance tumorale, elle s’accompagne d’une amélioration histologique de la NASH.

  • Open Access

    Long-term outcomes and temporal trends following liver transplantation for chronic liver disease in the intensive care unit

    by Magdalena Meszaros, José Ursic-Bedoya, Audrey Coilly, Claire Francoz, Cristophe Duvoux, Filomena Conti, Francois Faitot, Pauline Houssel-Debry, Jean Hardwigsen, Marie-Noelle Hilleret, et al.

  • Open Access

    Disparities in transplant access and outcomes after first cirrhosis decompensation in alcohol-related liver disease

    by José Ursic Bedoya, Charlotte De Choudens, Margaux Delhomme, Astrid Herrero, Stéphanie Faure, Lucy Meunier, Magdalena Meszaros, Georges-Philippe Pageaux, Claire Duflos


  • Top Cited Papers

    AI-Standardized Clinical Examination Training on OSCE Performance

    by Emma Lavigne, Antonio Lopez, Julien Frandon, Geoffrey Blaizot, Ludovic Gabellier, Salma Adham, José Ursic Bedoya, Jérémy Charriot, Thomas Thieblemont, Maha Badreddine, et al.


  • Long-term outcome following liver transplantation of patients with ACLF grade 3

    by Florent Artru, Sophie-Caroline Sacleux, Jose Ursic-Bedoya, Line Carole Ntandja Wandji, Alina Lutu, Sebastien L’HErmite, Clementine Levy, Marion Khaldi, Eric Levesque, Sebastien Dharancy, et al.


  • Hydrodynamic Transfection of Hepatocytes for the Study of Hepatocellular Carcinogenesis

    by José Ursic-Bedoya, Damien Gregoire

    Hydrodynamic tail vein injection (HTVi), also called hydrodynamic gene transfer (HGT), is attracting increasing interest for modeling hepatic carcinogenesis. This highly versatile approach reproducibly provides efficient in vivo transfection of hepatocytes with naked DNA. Here, we give an in-depth description of the injection procedure, which is key for the success of the method. HTVi requires the injection of a large volume of a solution containing plasmids into the tail vein of the mouse. The transient right heart overload created by the injection forces the blood to flow back into the hepatic veins, enlarging the endothelial fenestrae and permeabilizing a fraction of hepatocytes for a few seconds. This results in the uptake of plasmids by the permeabilized hepatocytes, giving rise to their in vivo transfection. Including the Sleeping Beauty transposon system among the injected plasmids leads to the stable transfection of a subset of hepatocytes. HTVi is a powerful technique which enables numerous applications in liver cancer biology, such as a study of oncogene cooperation, of tumor heterogeneity, and interaction with the tumor microenvironment. Key words In vivo transfection Hepatocytes Hydrodynamic gene delivery Mouse model Hepatocellular carcinoma


  • Open Access

    FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis

    by José Ursic-Bedoya, Guillaume Desandré, Carine Chavey, Pauline Marie, Arnaud Polizzi, Benjamin Rivière, Hervé Guillou, Eric Assenat, Urszula Hibner, Damien Gregoire

    FGF19 hormone has pleiotropic metabolic functions, including the modulation of insulin sensitivity, glucose/lipid metabolism and energy homeostasis. On top of its physiological metabolic role, FGF19 has been identified as a potentially targetable oncogenic driver, notably in hepatocellular carcinoma (HCC). Nevertheless, FGF19 remained an attractive candidate for treatment of metabolic disease, prompting the development of analogs uncoupling its metabolic and tumor-promoting activities. Using pre-clinical mice models of somatic mutation driven HCC, we assessed the oncogenicity of FGF19 in combination with frequent HCC tumorigenic alterations: p53 inactivation, CTNNB1 mutation, CCND1 or MYC overexpression. Our data revealed a strong oncogenic cooperation between FGF19 and MYC. Most importantly, we show that this oncogenic synergy is conserved with a FGF19-analog Aldafermin (NGM282), designed to solely mimic the hormone’s metabolic functions. In particular, even a short systemic treatment with recombinant proteins triggered rapid appearance of proliferative foci of MYC-expressing hepatocytes. The fact that FGF19 analog Aldafermin is not fully devoid of the hormone’s oncogenic properties raises concerns in the context of its potential use for patients with damaged, mutation-prone liver.


  • Open Access

    Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study

    by Elia Gigante, Mohamed Bouattour, José Ursic Bedoya, Hélène Regnault, Marianne Ziol, Eric Assenat, Valérie Paradis, Julien Calderaro, Nathalie Ganne‐Carrié, Karine Bouhier‐Leporrier, et al.

    Backgrounds: The efficacy of atezolizumab/bevacizumab has never been reported in patients with metastatic/unresectable combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA).Patients and Methods: We retrospectively included patients with a histological diagnosis of unresectable/metastatic cHCC‐CCA and treated with atezolizumab/bevacizumab (2020–2022) in 7 centers. Clinical and radiological features were collected at the beginning of atezolizumab/bevacizumab. We reported the radiological response using RECIST criteria, overall survival (OS) and progression‐free survival (PFS).Results: Sixteen patients with cHCC‐CCA were included and were predominantly male (75%) with advanced fibrosis/cirrhosis (69%). Nine patients received atezolizumab/bevacizumab as a first‐line systemic treatment, 5 as a second line, 1 as a third line and 1 as a fifth line. Severe digestive bleeding occurred in 2 patients. Among the 9 patients treated in the first line, 4 experienced radiological progression, 3 partial response and 1 had stable disease. Patients treated with atezolizumab/bevacizumab in the first line had a median OS of 13 months and a median PFS of 3 months. Among the 7 patients receiving atezolizumab/bevacizumab as a second line or more, 4 patients harbored a stable disease, 2 a partial response, and 1 a progressive disease.Conclusions: The combination of atezolizumab and bevacizumab showed signs of anti‐tumor efficacy in patients with unresectable/metastatic cHCC‐CCA.